熱門資訊> 正文
Fortress Biotech第二季度盈利预览
2026-08-12 05:35
- Fortress Biotech(FBIO) 0
- Fortress Biotech, Inc. 9.375% Series A Cumulative Redeemable Perpetual Preferred Stock(FBIOP) 0
- Nuvalent(NUVL) 0
- Fortress Biotech (FBIO) is scheduled to announce Q2 earnings results on Wednesday, August 12th, after market close.
- The consensus EPS Estimate is -$0.20 and the consensus Revenue Estimate is $18.3M (+11.5% Y/Y).
More on Fortress Biotech
- Fortress Biotech Just Netted $159 Million - Its Preferred Shares Could Be The Real Winner
- Fortress Biotech: Cash Above Market Cap And Royalty Upside Make This A Speculative Buy
- Fortress Biotech: Is It Time To Pay The Deferred Preferred Stock Dividends?
- Quant rating check: Top oncology peers as Nuvalent goes private in $10.6B deal with GSK
- Seeking Alpha’s Quant Rating on Fortress Biotech
推薦文章
風險及免責提示：以上內容僅代表作者的個人立場和觀點，不代表華盛的任何立場，華盛亦無法證實上述內容的真實性、準確性和原創性。投資者在做出任何投資決定前，應結合自身情況，考慮投資產品的風險。必要時，請諮詢專業投資顧問的意見。華盛不提供任何投資建議，對此亦不做任何承諾和保證。
